Surveying the NASH Drug Landscape

Other than Alzheimer's, few diseases are as big, in terms of R&D focus for the industry right now, as NASH (Nonalcoholic Steatohepatitis). It is easy to see why. As the developed world's population ages, gets more sedentary and grows more obese, incidence of the affliction has growing markedly in recent years.

The disorder will likely be the biggest cause of liver transplants in a few years, especially with hepatitis C on its way to being all-but-cured, thanks to new compounds from the likes of Gilead Sciences (GILD) , AbbVie (ABBV) and Merck (MRK) ....411 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.